HomeCompareDCPH vs KMB

DCPH vs KMB: Dividend Comparison 2026

DCPH yields 7.82% · KMB yields 5.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 KMB wins by $12.4K in total portfolio value· pulled ahead in Year 5
10 years
DCPH
DCPH
● Live price
7.82%
Share price
$25.59
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$33.6K
Annual income
$1,282.05
Full DCPH calculator →
KMB
KMB
● Live price
5.25%
Share price
$96.35
Annual div
$5.06
5Y div CAGR
17%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$45.9K
Annual income
$5,222.34
Full KMB calculator →

Portfolio growth — DCPH vs KMB

📍 KMB pulled ahead of the other in Year 5

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodDCPHKMB
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, DCPH + KMB cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
DCPH pays
KMB pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

DCPH
Annual income on $10K today (after 15% tax)
$664.32/yr
After 10yr DRIP, annual income (after tax)
$1,089.74/yr
KMB
Annual income on $10K today (after 15% tax)
$446.39/yr
After 10yr DRIP, annual income (after tax)
$4,438.99/yr
At 15% tax rate, KMB beats the other by $3,349.25/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of DCPH + KMB for your $10,000?

DCPH: 50%KMB: 50%
100% KMB50/50100% DCPH
Portfolio after 10yr
$39.7K
Annual income
$3,252.19/yr
Blended yield
8.18%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on DCPH right now

DCPH
Analyst Ratings
13
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$26.32
+2.9% upside vs current
Range: $25.00 — $30.00
Altman Z
7.4
Piotroski
3/9
KMB
Analyst Ratings
9
Buy
19
Hold
3
Sell
Consensus: Hold
Price Target
$123.00
+27.7% upside vs current
Range: $102.00 — $162.00
Altman Z
3.4
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

DCPH buys
0
KMB buys
0
No recent congressional trades found for DCPH or KMB in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricDCPHKMB
Forward yield7.82%5.25%
Annual dividend / share$2.00$5.06
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%17%
Portfolio after 10y$33.6K$45.9K
Annual income after 10y$1,282.05$5,222.34
Total dividends collected$10.4K$21.6K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyHold
Analyst price target$26.32$123.00

Year-by-year: DCPH vs KMB ($10,000, DRIP)

YearDCPH PortfolioDCPH Income/yrKMB PortfolioKMB Income/yrGap
1$11,482$781.56$11,314$614.45+$168.00DCPH
2$13,124$838.64$12,867$760.19+$257.00DCPH
3$14,938$895.89$14,713$945.27+$225.00DCPH
4$16,937$953.05$16,924$1,181.90+$13.00DCPH
5← crossover$19,133$1,009.87$19,596$1,486.64$463.00KMB
6$21,538$1,066.15$22,850$1,882.16$1.3KKMB
7$24,167$1,121.67$26,849$2,399.80$2.7KKMB
8$27,035$1,176.26$31,812$3,083.36$4.8KKMB
9$30,158$1,229.77$38,033$3,994.72$7.9KKMB
10$33,551$1,282.05$45,918$5,222.34$12.4KKMB

DCPH vs KMB: Complete Analysis 2026

DCPHStock

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

Full DCPH Calculator →

KMBConsumer Staples

Kimberly-Clark Corporation, together with its subsidiaries, manufactures and markets personal care and consumer tissue products worldwide. It operates through three segments: Personal Care, Consumer Tissue, and K-C Professional. The Personal Care segment offers disposable diapers, swimpants, training and youth pants, baby wipes, feminine and incontinence care products, and other related products under the Huggies, Pull-Ups, Little Swimmers, GoodNites, DryNites, Sweety, Kotex, U by Kotex, Intimus, Depend, Plenitud, Softex, Poise, and other brand names. The Consumer Tissue segment provides facial and bathroom tissues, paper towels, napkins, and related products under the Kleenex, Scott, Cottonelle, Viva, Andrex, Scottex, Neve, and other brand names. The K-C Professional segment offers wipers, tissues, towels, apparel, soaps, and sanitizers under the Kleenex, Scott, WypAll, Kimtech, and KleenGuard brands. The company sells household use products directly to supermarkets, mass merchandisers, drugstores, warehouse clubs, variety and department stores, and other retail outlets, as well as through other distributors and e-commerce; and away-from-home use products directly to manufacturing, lodging, office building, food service, and public facilities, as well as through distributors and e-commerce. Kimberly-Clark Corporation was founded in 1872 and is headquartered in Dallas, Texas.

Full KMB Calculator →
📬

Get this DCPH vs KMB comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

DCPH vs SCHDDCPH vs JEPIDCPH vs ODCPH vs KODCPH vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.